不同时机恢复ACEI/ARB对急性肾损伤后结局的影响
该多机构电子健康记录队列研究纳入5392例AKI后6个月内恢复ACEI/ARB的存活者,按恢复时机(出院前、出院后0-3个月、4-6个月)分析结局。采用目标试验设计的Cox模型显示,较早恢复与较低的全因死亡、MACCE、新发透析或ESRD风险相关,且未增加严重高钾血症和再入院AKI风险。
要点
- AKI后6个月内恢复ACEI/ARB,越早恢复全因死亡风险越低。
- 较早恢复未增加严重高钾血症和因AKI再入院的风险。
- 有ACEI/ARB适应症的AKI存活者应考虑早期恢复。
核心结论
- AKI后早期恢复ACEI/ARB与较低的死亡、心血管事件和ESRD风险相关,且不增加严重高钾血症或AKI再入院风险。
- 有ACEI/ARB适应症的患者应考虑早期恢复用药。
研究设计与样本
- 多机构电子健康记录队列研究,采用目标试验设计。
- 纳入5392例AKI后6个月内恢复ACEI/ARB的存活者。
- 按恢复时机分为出院前、出院后0-3个月、出院后4-6个月三组。
- 使用Cox比例风险模型估计结局的风险比(HR)。
主要发现
- 较早恢复与较低的全因死亡、MACCE、MACCE相关死亡、新发透析或ESRD风险相关(趋势检验P < 0.001)。
- 与出院后4-6个月恢复相比,出院前恢复的死亡HR为0.88(95%CI 0.83-0.93)。
- 与出院后4-6个月恢复相比,出院后0-3个月恢复的死亡HR为0.89(95%CI 0.85-0.94)。
- 在有既往ACEI/ARB适应症合并症的亚组中,出院前恢复的死亡HR为0.85(95%CI 0.80-0.90),0-3个月恢复的HR为0.88(95%CI 0.83-0.93),趋势检验P < 0.001。
- 较早恢复未增加严重高钾血症和因AKI再入院的风险。
临床怎么用
- 对AKI存活者,若存在ACEI/ARB适应症,可考虑在出院前或出院后尽早恢复用药。
- 恢复ACEI/ARB时需监测严重高钾血症和复发性AKI,但研究未显示早期恢复增加这些风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Evidence suggests a survival benefit from resuming angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) post acute kidney injury (AKI) compared to nonuse; however, the optimal timing and its impact on outcomes are unclear. The risks of earlier resumption, such as recurrent AKI or hyperkalemia, remain unexplored. METHODS: Using multiinstitutional electronic health records, we analyzed the relationship between 3 ACEI or ARB (ACEI/ARB) resumption timelines post-AKI (prior to discharge, 0-3 months, and 4-6 months postdischarge) and outcomes including all-cause mortality, major adverse cardiac and cerebrovascular events (MACCEs), dialysis initiation or end-stage renal disease (ESRD), severe hyperkalemia, and recurrent AKI with hospitalization. Cox proportional models estimated hazard ratios (HRs) for outcomes across different resumption timings, following a target trial design. RESULTS: Among 5392 AKI survivors resuming ACEI/ARB within 6 months post-AKI, earlier resumption was associated with lower mortality, MACCE, MACCE-related mortality, new dialysis initiation or ESRD (P < 0.001 in trend tests), without increased risks of severe hyperkalemia and re-AKI admissions. Early resumption has a lower mortality compared to 4 to 6 months postdischarge (before discharge, HR: 0.88, 95% confidence interval [CI]: 0.83-0.93; 0-3 months, HR: 0.89, 95% CI: 0.85-0.94). Subgroup analysis showed a lower mortality HR from earlier resumption among AKI survivors with prior ACEI/ARB comorbidity indications (P < 0.001 in trend tests; before discharge, HR: 0.85, 95% CI: 0.80-0.90; 0-3 months, HR: 0.88, 95% CI: 0.83-0.93). CONCLUSION: Our cohort demonstrates lower risks for mortality, cardiovascular events, and ESRD with early ACEI/ARB resumption, without heightened risks of severe hyperkalemia or rehospitalization for AKI. Early resumption should be considered for patients with indications for ACEI/ARB.
引用
- Chen JJ, Lee CC, Yen CL, et al. Impact of Different Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blocker Resumption Timing on Post Acute Kidney Injury Outcomes. Kidney Int Rep. 2024. PMID: 39534209. doi:10.1016/j.ekir.2024.08.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。